Discover 1,239 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,239
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
for
Advanced Solid Tumors
Location: Nashville TN, Louisville KY, Atlanta GA, Greenville SC,
Sponsor: DualityBio Inc.
Sex: All
Age: 18+
Code: NCT05914116
Phase 1, Phase 2, Recruiting
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
for
Solid Tumors, Neoplasms
Location: Nashville TN, Birmingham AL, Detroit MI,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT06431594
Phase 1, Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
for
Solid Tumor, Adult
Location: Nashville TN, Huntersville NC, Chicago IL,
Sponsor: DualityBio Inc.
Sex: All
Age: 18+
Code: NCT06554795
Phase 1, Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
for
Multiple Myeloma
Location: Nashville TN, Macon GA, Bridgeton MO, Springfield MO,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT07227311
Phase 2, Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
for
Neoplasms, Colorectal, Neoplasms
Location: Nashville TN, Canton OH, Detroit MI, Hamilton, Toronto,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT07213609
Phase 1, Phase 2, Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
for
Renal Cell Carcinoma (RCC),
Location: Nashville TN, Indianapolis IN, Durham NC, Chicago IL,
Sponsor: Exelixis
Sex: All
Age: 18+
Code: NCT05176483
Phase 1, Recruiting
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
for
Adenocarcinoma, Carcinoma, Pancreatic Ductal
Location: Nashville TN, Atlanta GA, Cincinnati OH, Goshen IN,
Sponsor: Corcept Therapeutics
Sex: All
Age: 18+
Code: NCT07259317
Phase 2, Recruiting
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
for
Neoplasms
Location: Nashville TN, Reunion FL, Dallas TX, Philadelphia PA,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT07277270
Phase 1, Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Location: Nashville TN, St Louis MO, Lake Mary FL,
Sponsor: MOMA Therapeutics
Sex: All
Age: 18+
Code: NCT06545942
Phase 1, Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
for
Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC),
Location: Nashville TN, St Louis MO, Durham NC, Fairfax VA,
Sponsor: Pheon Therapeutics
Sex: All
Age: 18+
Code: NCT07127874
Phase 1, Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
for
Multiple Myeloma
Location: Nashville TN, Chattanooga TN, Chapel Hill NC, Canton OH,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT05714839
Phase 1, Phase 2, Recruiting
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
for
Neoplasms, Prostate
Location: Nashville TN, Rochester MN, Toronto, East Brunswick NJ,
Sponsor: GlaxoSmithKline
Sex: Male
Age: 18+
Code: NCT06990880
Phase 1, Phase 2, Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
for
Neoplasms, Head and Neck
Location: Nashville TN, Chattanooga TN, Lexington KY, Atlanta GA,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT06256588
Phase 3, Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP